marketshareAI
Theme

ValiRx

VALHealthcare
0.3850GBX
0.00%
Market Cap
2.86M
Volume
1.5M
9% of avg
P/E Ratio
-0.21
EPS (TTM)
-1.86
Beta
-0.75
Day Range
0.3700p - 0.4000p
52 Week Range
0.2200p0.3850p0.8950p
0.3850p

Upcoming Events

Early February 2026
Deadline for University of Dundee prosenescence asset evaluation
Q2 2026
Planned filing of new application-based patents for Val201
3 June 2026
Conclusion of the evaluation period
High Impact Event
5 August 2026
Conclusion of the new 12-month evaluation agreement between ValiRx and Stingray Bio
9 September 2026
Completion of the evaluation period
High Impact Event
4 August 2027
Potential buyout of rights by either party
High Impact Event
VAL
BAD

ValiRx Announces Discounted Equity Raise

The biotechnology company has raised £400 through a discounted equity placing, raising concerns about its financial position and growth outlook.

VAL
GOOD

ValiRx Enters Evaluation Agreement with McGill University and IRICoR

The biopharmaceutical company has entered a new evaluation and material transfer agreement with a Canadian university and research organization to develop a promising RNA Helicase inhibitor asset.

VAL
NEUTRAL

ValiRx Enters Evaluation Agreement for RNA Helicase Inhibitor with McGill and IRICoR

The biopharmaceutical company has entered a nine-month evaluation agreement with a Canadian university and non-profit to develop a second-generation RNA Helicase inhibitor. The agreement includes potential seed funding and licensing options.

VAL
NEUTRAL

ValiRx Announces Change in Shareholding

The biopharmaceutical company has announced a change in its shareholding structure.

VAL
NEUTRAL

ValiRx Announces Change in Shareholding

The biopharmaceutical company has announced a change in shareholding, with no further details provided.

VAL
NEUTRAL

ValiRx Announces Change in Shareholding

The biopharmaceutical company ValiRx has announced a change in shareholding.

VAL
NEUTRAL

ValiRx Announces Change in Shareholding

The biopharmaceutical company has announced a change in shareholding, with no further details provided.

VAL
NEUTRAL

ValiRx Announces Change in Shareholding

The biopharmaceutical company has announced a change in its shareholding structure.

VAL
NEUTRAL

ValiRx Announces Change in Shareholding

The biopharmaceutical company has announced a change in its shareholding structure.

VAL
GOOD

ValiRx Announces £902,000 Fundraising to Advance Pipeline

The life sciences company announces a £902,000 fundraising to advance its pipeline, including investments in R&D and preclinical development.